David R. Bellaire

• 
  www.pcmanet.org/events/pevents/ps_102305.htm - [Cached Version]
  Published on: 10/25/2005    Last Visited: 3/3/2007  

  David R. Bellaire, Partner, Bain & Company, Inc.
  
  Trends that Shape the PBM Industry's Future
  ...
  David R. Bellaire, Partner, Bain & Company, Inc. (PRESENTATION NOT AVAILABLE)
  
  Trends that Shape the PBM Industry's Future

• 
  6th Annual Philadelphia-Japan Health Sciences Dialogue... - [Cached Version]
  Published on: 8/13/2004    Last Visited: 10/18/2005  

  David Bellaire, Partner, Bain & Company, Inc.Sales & Marketing
  
  Taro Iwamoto, Company Operating Officer, Otsuka Pharmaceutical Co., Ltd.

• 
  Bain & Company: Publications - Results - [Cached Version]
  Published on: 6/19/2005    Last Visited: 6/19/2005  

  Highly automated and thus hugely profitable-they don't have stores to build and staff-PBMs can fill and mail a prescription for as low as $2.50, a fraction of what it costs drugstores, according to Bain partner David Bellaire, an expert on pharmacy operations.Bellaire says those lower costs mean cheaper drugs for consumers.

• 
  BostonWorks - Jobs, Events, and Information from The... - [Cached Version]
  Published on: 3/19/2004    Last Visited: 11/9/2004  

  David Bellaire has joined Bain & Co.'s Boston office as a partner in their global healthcare practice.Bellaire had been an executive vice president at NDCHealth.

• 
  Drug Topics - Chains ponder responses to mandatory... - [Cached Version]
  Published on: 4/18/2005    Last Visited: 5/22/2005  

  Another speaker, David R. Bellaire, of the consulting firm Bain & Co., pointed out that pharmacies will continue to lose not only prescription business, but also whatever front-store sales Rx-related foot traffic brings in. Under fairly conservative estimates, some pharmacies could be facing revenue losses of up to 40% over the next several years, he said.In 2001, 6% of employer drug benefit plans included some form of mandatory mail-order provisions.That figure rose to 24% in 2004.
  
  Furthermore, pharmacies can anticipate little support from drug manufacturers, which are facing a spate of their own problems, Bellaire noted.
  ...
  Assuming PBMs pass at least 90% of these rebates on to the health plan payers, it is virtually impossible for retail pharmacies to compete on price with PBMs and turn a profit, according to Bellaire.
  
  Retail pharmacy chains should adopt a long-term strategy of partnering with a PBM that has a mail-order facility, Bellaire suggested.In his model, prescriptions would be dropped off at the retail pharmacy and faxed to the partner mail-order facility, which would fill the Rx and label the bottle with the chain pharmacy's brand name.

• 
  Japan America Society of Greater Philadelphia - 2005... - [Cached Version]
  Published on: 1/1/2005    Last Visited: 9/11/2006  

  David BellairePartner, Bain & Company, Inc.

• 
  MedAccess Articles - From 'One Size Fits All' To... - [Cached Version]
  Published on: 6/16/2004    Last Visited: 8/8/2006  

  "Depending on the therapy and the disease being treated, it is not uncommon for persistency to fall to 40% to 50% within four months of therapy's initiation," says Dave Bellaire, an executive vice president at health-information company, NDCHealth in Atlanta.

• 
  NDCHealth - Industry Forum 2004 - Speakers - [Cached Version]
  Published on: 10/29/2004    Last Visited: 10/29/2004  

  David Bellaire
  ...
  David BellaireExecutive Vice President, Research & Consulting, Pharmaceutical Benefit Operations and Corporate Marketing, NDCHealth
  
  Dave Bellaire brings to his current role more than 17 years of healthcare professional service,complemented by 10 years in provider, medical, product and health service consulting and management.
  
  Bellaire joined NDCHealth in 2003 from Acumen Sciences and Booz Allen Hamilton, where as a lead partner, he served the pharmaceutical, biotechnology, advanced medical product and insurance sectors.His other executive management experience includes: merger, acquisition, affiliation development and strategic positioning for plans and providers; operations management in community and academic health environments and logistics support for ethical drug and medical product companies.He also founded and later successfully sold Canada Prosthetics, which designed and distributed orthotic and neural prostheses.
  
  Bellaire has served on the faculty of Northwestern University Medical School.His multiple graduate degrees were received with distinction from Northwestern University.He is a published author and frequent presenter to domestic and foreign professional associations.

• 
  On The Move - [Cached Version]
  Published on: 11/1/2004    Last Visited: 10/21/2005  

  David R. Bellaire has joined consulting firm Bain & Company as a partner in its Global Healthcare Practice.

• 
  Reuters Summit - No let-up in global drug price... - [Cached Version]
  Published on: 11/18/2004    Last Visited: 11/18/2004  

  David Bellaire, a partner with Bain & Co.Inc., said just under half of the world's prescription medicines were consumed in the United States but the country accounted for three-quarters of the industry's profit.
  
  The difference reflects the premium paid by U.S. consumers.In future, that may simply not be tolerated by the U.S. public.
  
  "If the developed nations of the world were to bear their fair share of innovation expense, we could drop U.S. drug prices between 25 and 30 percent overnight without affecting pharmaceutical and biotechnology company margins," Bellaire said.

Page:  1 2